进展性与非进展性脑梗死患者阿托伐他汀治疗前后T淋巴细胞亚群的变化

目的通过研究进展性和非进展性脑梗死在阿托伐他汀治疗前后T淋巴细胞亚群的变化,探讨他汀类药物治疗脑梗死的免疫学机制。方法选择53例急性脑梗死患者,分为进展和非进展组,应用流式细胞分析仪检测两组患者阿托伐他汀治疗前后T淋巴细胞亚群相对计数,并且根据患者治疗前后神经功能缺损程度进行效果评价。结果进展组治疗前后比较:CD4+T细胞和CD4/CD8值显著升高,CD8+T细胞显著降低;非进展组治疗前后比较:CD4/CD8值显著升高;两组治疗前后神经功能缺损评分自身比较,均明显降低。结论阿托伐他汀治疗前后,进展性和非进展性脑梗死患者体内T淋巴细胞亚群分布发生了不同程度的变化。阿托伐他汀可能通过提高CD4+T细胞水平,促进急性脑梗死的恢复。

Changes of T-lymphocyte subsets in progressive and non progressive cerebral infarction before and after treatment with atorvastatin

Objective To study the change of T-lymphocyte subsets in the patients with progressive and non progressive cerebral irdarction before and after treatment with atorvastatin, and explore the possible mechanism of statin on treating cerebral infarction further. Methods 53 patients with acute cerebral infarction （ACI） were selected in our study and divided into two groups： progressive and non progressive groups. The peripheral blood T-lymphocyte subsets relative counting were detected by flow cytometry analysis before and after treatment with statin. Evaluated the impact of the statin in ACI according to the degree of NIHSS. Results Progressive group： the percentage of CD8＋ T cell was significantly lower（ P 〈0.05） , while the rate of CD4＋/ CD8＋ T and the percentage of CI）4＋ T cell increased notably after treatment with atoiwastatin（P 〈0.05） ; Non progressive group： the rate of CD4＋/ CD8＋ T increased notably after treatment with statin（ P 〈0.05 ） ; The improvements of neurological deficit grades were notable in two groups. Conclusion In two groups, atorvastatin could change the distribution of the T-lymphocyte subsets and improve the degree of NIHSS in patients with ACI by means of increasing CD4＋T cell.